



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Khan et al.

Serial No.: 10/821,240

Filed: April 8, 2004

For: METHODS AND USES FOR
PROTEIN BREAKDOWN PRODUCTS

Confirmation No.: 9732

Examiner: K. Skowronek

Group Art Unit: 1631

Attorney Docket No.: 2183.03-6384US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV962534415US

Date of Deposit with USPS: May 9, 2007

Person making Deposit: Cat Bratton

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

U.S. Patent Documents

U.S. Patent No.

US - 5,856,440

Publication Date

01-1999

Patentee

Wang

Other Documents

ABEYAMA et al., A role of NF-kappaB-dependent gene transactivation in sunburn. The Journal of Clinical Investigation, Vol. 105, No. 12, pp. 1751-59, June 2000.

COOK et al., Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis. Journal of Neurological Sciences, Vol. 152, pp. 172-81, 1997.

FLORES et al., NFkappaB and AP-1 DNA binding activity in patients with multiple sclerosis. J. Neuroimmunol. Vol. 135, No. 1-2, pp. 141-7, February 2003.

OKA et al., Immunosuppression in organ transplantation, Japanese Journal of Pharmacology, Vol. 71, No 2, pp. 89-100, June 1996.

ZHOU et al., Transplantation tolerance in NF-kappaB-impaired mice is not due to regulation but is prevented by transgenic expression of Bcl-xL. The Journal of Immunology, Vol. 174, No. 6, pp. 3447-53, March 2005.

This Supplemental Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits.

The fee pursuant to 37 C.F.R. § 1.17(p) is authorized to be charged to TraskBritt Deposit Account No. 20-1469.

Respectfully submitted,



Kelly A. Echols
Registration No. 55,911
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: May 9, 2007

KAE/bv

Enclosures: Form PTO/SB/08

Cited Non-U.S. Patent Documents

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

MAY 09 2007 ²¹ (use as many sheets as necessary)

Sheet	100	of
-------	----------------	----

Complete if Known

Application Number	10/821,240
Filing Date	April 8, 2004
First Named Inventor	Khan et al.
Group Art Unit	1631
Examiner Name	K. Skowronek
Attorney Docket Number	2183.03-6384US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

of

Complete if Known

Application Number	10/821,240
Filing Date	April 8, 2004
First Named Inventor	Khan et al.
Group Art Unit	1631
Examiner Name	K. Skowronek
Attorney Docket Number	2183 03-6384US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ABEYAMA et al., A role of NF-kappaB-dependent gene transactivation in sunburn. The Journal of Clinical Investigation, Vol. 105, No. 12, pp. 1751-59, June 2000.	
		COOK et al., Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis. Journal of Neurological Sciences, Vol. 152, pp. 172-81, 1997.	
		FLORES et al., NFkappaB and AP-1 DNA binding activity in patients with multiple sclerosis. J. Neuroimmunol. Vol. 135, No. 1-2, pp. 141-7, February 2003.	
		OKA et al., Immunosuppression in organ transplantation, Japanese Journal of Pharmacology, Vol. 71, No 2, pp. 89-100, June 1996.	
		ZHOU et al., Transplantation tolerance in NF-kappaB-impaired mice is not due to regulation but is prevented by transgenic expression of Bcl-xL. The Journal of Immunology, Vol. 174, No. 6, pp. 3447-53, March 2005.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.